| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | selumetinib:GDC-0941 (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | 0.075 | 0.2 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.038 | 0.2 |
| mRNA | BRD-K33199242 | CTRPv2 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.043 | 0.2 |
| mRNA | 681640 | GDSC1000 | pan-cancer | AAC | 0.048 | 0.2 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |